Notice2022-17730
Government-Owned Inventions; Availability for Licensing
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
August 18, 2022
Issuing agencies
Health and Human Services DepartmentNational Institutes of Health
Abstract
The invention listed below is owned by an agency of the U.S. Government and is available for licensing to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.
Full Text
<html>
<head>
<title>Federal Register, Volume 87 Issue 159 (Thursday, August 18, 2022)</title>
</head>
<body><pre>
[Federal Register Volume 87, Number 159 (Thursday, August 18, 2022)]
[Notices]
[Pages 50864-50865]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2022-17730]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The invention listed below is owned by an agency of the U.S.
Government and is available for licensing to achieve expeditious
commercialization of results of federally-funded research and
development. Foreign patent applications are filed on selected
inventions to extend market coverage for companies and may also be
available for licensing.
FOR FURTHER INFORMATION CONTACT: Dawn Taylor-Mulneix at 301-767-5189,
or <a href="/cdn-cgi/l/email-protection#bdd9dccad393c9dcc4d1d2cf90d0c8d1d3d8d4c5fdd3d4d593dad2cb"><span class="__cf_email__" data-cfemail="84e0e5f3eaaaf0e5fde8ebf6a9e9f1e8eae1edfcc4eaedecaae3ebf2">[email protected]</span></a>. Licensing information may be obtained
by communicating with the Technology Transfer and Intellectual Property
Office, National Institute of Allergy and Infectious Diseases, 5601
Fishers Lane, Rockville, MD 20852; tel. 301-496-2644. A signed
Confidential Disclosure Agreement will be required to receive copies of
unpublished information related to the invention.
SUPPLEMENTARY INFORMATION:
SARS-CoV-2 Infection of Human Lung Epithelial Cells Triggers a Cell-
Mediated Acute Fibrin Fibrosis
Description of Technology
Scientists at National Institute of Allergy and Infectious Diseases
(NIAID) have developed a method of treatment for virus-induced lung
fibrosis using nebulized thrombin inhibitors. Since March 2020, the
World Health Organization (WHO) estimates that 564 million people have
been infected with SARS-CoV-2 world-wide. Lung fibrosis is a major
factor associated with SARS-CoV-2 infections and can contribute to
mortality. Additionally, severe SARS-CoV-2 cases can result in long-
term pulmonary disease due to lung fibrosis. At present, attempts to
treat lung fibrosis developed during a SARS-CoV-2 infection using
intravenous heparin have been unsuccessful.
NIAID scientists have discovered a previously unknown acute
fibrosis mechanism mediated by SARS-CoV-2 infected primary lung
epithelium, and have developed an innovative method of treating lung
fibrosis using nebulized thrombin inhibitors.
This technology is available for licensing for commercial
development
[[Page 50865]]
in accordance with 35 U.S.C. 209 and 37 CFR part 404, as well as for
further development and evaluation under a research collaboration.
Potential Commercial Applications
<bullet> Innovative method of treatment for virus-induced lung fibrosis
<bullet> A multi-targeted approach could decrease lung-term symptoms
associated with SARS-CoV-2
Competitive Advantages
<bullet> Addresses the pathology at the proper location instead of
indiscriminately
Development Stage
<bullet> Pre-Clinical
Inventors: Peter Sun and Rachel Erickson, all of NIAID.
Intellectual Property: US Provisional Application 63/388,498 (HHS
Reference No. E-157-2022-0-US-01) filed on 12 July 2022.
Licensing Contact: To license this technology, please contact Dawn
Taylor-Mulneix at 301-767-5189, or <a href="/cdn-cgi/l/email-protection#1a7e7b6d74346e7b6376756837776f76747f73625a747372347d756c"><span class="__cf_email__" data-cfemail="c7a3a6b0a9e9b3a6beaba8b5eaaab2aba9a2aebf87a9aeafe9a0a8b1">[email protected]</span></a>, and
reference E-157-2022.
Collaborative Research Opportunity: The National Institute of
Allergy and Infectious Diseases is seeking statements of capability or
interest from parties interested in collaborative research to further
develop, evaluate or commercialize this technology. For collaboration
opportunities, please contact Dawn Taylor-Mulneix at 301-767-5189, or
<a href="/cdn-cgi/l/email-protection#4e2a2f3920603a2f3722213c63233b22202b27360e20272660292138"><span class="__cf_email__" data-cfemail="e682879188c892879f8a8994cb8b938a88838f9ea6888f8ec8818990">[email protected]</span></a>.
Dated: August 12, 2022.
Surekha Vathyam,
Deputy Director, Technology Transfer and Intellectual Property Office,
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2022-17730 Filed 8-17-22; 8:45 am]
BILLING CODE 4140-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on August 18, 2022.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.